This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Amazon CEO Tops Forbes Rich List, Shares Hit 52-Week High
by Zacks Equity Research
Amazon (AMZN) attains 52-week high on AWS strength and diversified presence. Meanwhile, CEO Jeff Bezos tops Forbes Rich List for the first time.
Amedisys (AMED) Strong on Buyouts & Solid Personal Care Unit
by Zacks Equity Research
Amedisys (AMED) forges ahead with buyouts to boost capacity and geographical presence.
Abbott Gets FDA Nod for Masters HP 15mm, Boosts Portfolio
by Zacks Equity Research
Abbott (ABT) adopts initiatives to strengthen the Structural Heart business within the Medical Device segment.
Allscripts (MDRX) Launches Avenel to Revamp EHR Platform
by Zacks Equity Research
Allscripts' (MDRX) innovation team comes up with a user-friendly application, Avenel, to aid patients and clinicians through EHR.
Chimerix Q4 Loss Narrower Than Expected, Revenues Exceed
by Zacks Equity Research
Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.
Boston Scientific Acquires EMcision, Boosts Endoscopy Unit
by Zacks Equity Research
Boston Scientific (BSX) adopts initiatives to strengthen the Endoscopy business.
Abaxis Banks on Strong Veterinary Business Amid Margin Woes
by Zacks Equity Research
Abaxis' (ABAX) strong performance in Veterinary consumables drives growth. Weak gross and operating margin scenario is a concern.
3 Reasons Why You Should Invest in athenahealth (ATHN) Stock
by Zacks Equity Research
athenahealth (ATHN) rides on solid fourth-quarter results and strong fundamentals.
Here's Why Teleflex Has Been Losing Ground Since Q4 Earnings
by Zacks Equity Research
Teleflex's (TFX) contracted Q4 adjusted operating margin is discouraging.
BioTelemetry (BEAT) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
BioTelemetry (BEAT) sees strong Q4 results, courtesy of solid acquisitions and promising performance by the MCT platform.
eBay's (EBAY) Marketplace is Expected to Do Well in 2018
by Zacks Equity Research
eBay (EBAY) is making all efforts to improve its Marketplace business.
JD.com (JD) Q4 Earnings Miss Estimates, Revenues Improve Y/Y
by Zacks Equity Research
JD.com's (JD) fourth-quarter earnings are impacted by higher spending in growth areas including fulfillment centers and increasing competition from Alibaba.
Bio-Rad (BIO) Q4 Earnings Improve Y/Y, Revenues Top Mark
by Zacks Equity Research
Bio-Rad's (BIO) strong sales in Q4 ride high on a robust performance at Life Science product lines.
OPKO Health (OPK) Q4 Earnings Decline Y/Y, Margins Down
by Zacks Equity Research
OPKO Health (OPK) posts lackluster Q4 numbers due to rising operating expenses owing to investments associated with the launch of RAYALDEE and consistent investments in the pharmaceutical pipeline.
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Strong performance at Dental & Healthcare Consumables segment drives DENTSPLY's (XRAY) Q4 sales.
Patterson Companies (PDCO) Misses on Q3 Earnings, Cuts View
by Zacks Equity Research
Lower sales and gross-margin compression mars Patterson Companies' (PDCO) results in Q3.
Alarm.com (ALRM) Q4 Earnings Top Estimates, Issues 2018 View
by Zacks Equity Research
Alarm.com (ALRM) reports strong fourth-quarter results on the back of higher SaaS and license revenues, and portfolio expansion.
Masimo (MASI) Beats on Q4 Earnings & Revenues, View Positive
by Zacks Equity Research
Strong performance in Product revenues drove Masimo's (MASI) fourth-quarter 2017 results.
DexCom (DXCM) Surpasses Earnings & Revenue Estimates in Q4
by Zacks Equity Research
DexCom (DXCM) rides high on strength in all segments in Q4.
Wright Medical (WMGI) Beats Q4 Earnings & Revenue Estimates
by Zacks Equity Research
Wright Medical (WMGI) delivers promising Q4 results on the back of strength in its flagship Upper Extremities segment, despite declining international revenues of the Lower Extremities.
Amedisys (AMED) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Amedisys (AMED) registers strong growth across all segments in Q4.
Penumbra (PEN) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
Penumbra (PEN) sees strong growth across all geographical regions and product lines in Q4.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Inogen (INGN) reports impressive Q4 financial results on the back of strong business-to-business and direct-to-consumer sales growth.
Integra LifeSciences (IART) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Integra LifeSciences's (IART) solid Q4 revenue growth was primarily driven by high organic revenues and better-than-expected performance by the recently-acquired businesses.
Booking Holdings (BKNG) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Booking Holdings' (BKNG) fourth-quarter results are driven by significant contributions from investments in people, systems and marketing.